-
1
-
-
0009013631
-
Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
-
DOI 10.1038/ng0396-312
-
Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, et al. (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12: 312-314. (Pubitemid 26080092)
-
(1996)
Nature Genetics
, vol.12
, Issue.3
, pp. 312-314
-
-
Longley, B.J.1
Tyrrell, L.2
Lu, S.-Z.3
Ma, Y.-S.4
Langley, K.5
Ding, T.-G.6
Duffy, T.7
Jacobs, P.8
Tang, L.H.9
Modlin, I.10
-
2
-
-
0034986344
-
Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings
-
Horny HP, Valent P (2001) Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 25: 543-551.
-
(2001)
Leuk Res
, vol.25
, pp. 543-551
-
-
Horny, H.P.1
Valent, P.2
-
3
-
-
0034983045
-
Diagnostic criteria and classification of mastocytosis: A consensus proposal
-
DOI 10.1016/S0145-2126(01)00038-8, PII S0145212601000388
-
Valent P, Horny HP, Escribano L, Longley BJ, Li CY, et al. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25: 603-625. (Pubitemid 32506768)
-
(2001)
Leukemia Research
, vol.25
, Issue.7
, pp. 603-625
-
-
Valent, P.1
Horny, H.-P.2
Escribano, L.3
Longley, B.J.4
Li, C.Y.5
Schwartz, L.B.6
Marone, G.7
Nunez, R.8
Akin, C.9
Sotlar, K.10
Sperr, W.R.11
Wolff, K.12
Brunning, R.D.13
Parwaresch, R.M.14
Austen, K.F.15
Lennert, K.16
Metcalfe, D.D.17
Vardiman, J.W.18
Bennett, J.M.19
-
4
-
-
0028856070
-
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
-
Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, et al. (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92: 10560-10564.
-
(1995)
Proc Natl Acad Sci U S A
, vol.92
, pp. 10560-10564
-
-
Nagata, H.1
Worobec, A.S.2
Oh, C.K.3
Chowdhury, B.A.4
Tannenbaum, S.5
-
5
-
-
33749368009
-
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
-
DOI 10.1182/blood-2006-04-015545
-
Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, et al. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108: 2366-2372. (Pubitemid 44497521)
-
(2006)
Blood
, vol.108
, Issue.7
, pp. 2366-2372
-
-
Garcia-Montero, A.C.1
Jara-Acevedo, M.2
Teodosio, C.3
Sanchez, M.L.4
Nunez, R.5
Prados, A.6
Aldanondo, I.7
Sanchez, L.8
Dominguez, M.9
Botana, L.M.10
Sanchez-Jimenez, F.11
Sotlar, K.12
Almeida, J.13
Escribano, L.14
Orfao, A.15
-
6
-
-
0036493872
-
The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations
-
DOI 10.1182/blood.V99.5.1741
-
Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, et al. (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 1741-1744. (Pubitemid 34533049)
-
(2002)
Blood
, vol.99
, Issue.5
, pp. 1741-1744
-
-
Ma, Y.1
Zeng, S.2
Metcalfe, D.D.3
Akin, C.4
Dimitrijevic, S.5
Butterfield, J.H.6
McMahon, G.7
Jack, L.B.8
-
7
-
-
0043169405
-
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
-
DOI 10.1016/S0301-472X(03)00112-7
-
Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, et al. (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31: 686-692. (Pubitemid 36945381)
-
(2003)
Experimental Hematology
, vol.31
, Issue.8
, pp. 686-692
-
-
Akin, C.1
Brockow, K.2
D'Ambrosio, C.3
Kirshenbaum, A.S.4
Ma, Y.5
Longley, B.J.6
Metcalfe, D.D.7
-
8
-
-
33645687784
-
D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
-
DOI 10.1182/blood-2005-10-3969
-
Shah NP, Lee FY, Luo R, Jiang Y, Donker M, et al. (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108: 286-291. (Pubitemid 43990640)
-
(2006)
Blood
, vol.108
, Issue.1
, pp. 286-291
-
-
Shah, N.P.1
Lee, F.Y.2
Luo, R.3
Jiang, Y.4
Donker, M.5
Akin, C.6
-
9
-
-
52449085884
-
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
-
Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, et al. (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14: 3906-3915.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3906-3915
-
-
Verstovsek, S.1
Tefferi, A.2
Cortes, J.3
O'Brien, S.4
Garcia-Manero, G.5
-
10
-
-
84872800619
-
KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial
-
Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, et alKIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. Blood (Annual Meeting Abstracts). November 2012 (120: 799.).
-
Blood (Annual Meeting Abstracts). November 2012
, vol.120
, pp. 799
-
-
Gotlib, J.1
Kluin-Nelemans, H.C.2
George, T.I.3
Akin, C.4
Sotlar, K.5
-
11
-
-
67349145955
-
Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates
-
Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, et al. (2009) Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23: 900-904.
-
(2009)
Leukemia
, vol.23
, pp. 900-904
-
-
Tefferi, A.1
Levine, R.L.2
Lim, K.H.3
Abdel-Wahab, O.4
Lasho, T.L.5
-
12
-
-
84865062086
-
Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis
-
Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, et al. (2012) Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One 7: e43090.
-
(2012)
PLoS One
, vol.7
-
-
Traina, F.1
Visconte, V.2
Jankowska, A.M.3
Makishima, H.4
O'Keefe, C.L.5
-
13
-
-
79952336888
-
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
-
Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, et al. (2011) Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 96: 459-463.
-
(2011)
Haematologica
, vol.96
, pp. 459-463
-
-
Wilson, T.M.1
Maric, I.2
Simakova, O.3
Bai, Y.4
Chan, E.C.5
-
14
-
-
80052461558
-
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
-
Ito S, Shen L, Dai Q, Wu SC, Collins LB, et al. (2011) Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333: 1300-1303.
-
(2011)
Science
, vol.333
, pp. 1300-1303
-
-
Ito, S.1
Shen, L.2
Dai, Q.3
Wu, S.C.4
Collins, L.B.5
-
15
-
-
80052495940
-
Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA
-
He YF, Li BZ, Li Z, Liu P, Wang Y, et al. (2011) Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333: 1303-1307.
-
(2011)
Science
, vol.333
, pp. 1303-1307
-
-
He, Y.F.1
Li, B.Z.2
Li, Z.3
Liu, P.4
Wang, Y.5
-
16
-
-
66249137734
-
Mutation in TET2 in myeloid cancers
-
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, et al. (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289-2301.
-
(2009)
N Engl J Med
, vol.360
, pp. 2289-2301
-
-
Delhommeau, F.1
Dupont, S.2
Della Valle, V.3
James, C.4
Trannoy, S.5
-
17
-
-
67349124376
-
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
-
Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, et al. (2009) TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23: 905-911.
-
(2009)
Leukemia
, vol.23
, pp. 905-911
-
-
Tefferi, A.1
Pardanani, A.2
Lim, K.H.3
Abdel-Wahab, O.4
Lasho, T.L.5
-
18
-
-
67649876132
-
Acquired mutations in TET2 are common in myelodysplastic syndromes
-
Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, et al. (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41: 838-842.
-
(2009)
Nat Genet
, vol.41
, pp. 838-842
-
-
Langemeijer, S.M.1
Kuiper, R.P.2
Berends, M.3
Knops, R.4
Aslanyan, M.G.5
-
19
-
-
79960064353
-
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
-
Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, et al. (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20: 11-24.
-
(2011)
Cancer Cell
, vol.20
, pp. 11-24
-
-
Moran-Crusio, K.1
Reavie, L.2
Shih, A.3
Abdel-Wahab, O.4
Ndiaye-Lobry, D.5
-
20
-
-
79960062301
-
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis
-
Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, et al. (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20: 25-38.
-
(2011)
Cancer Cell
, vol.20
, pp. 25-38
-
-
Quivoron, C.1
Couronne, L.2
Della Valle, V.3
Lopez, C.K.4
Plo, I.5
-
21
-
-
80052285127
-
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies
-
Li Z, Cai X, Cai CL, Wang J, Zhang W, et al. (2011) Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118: 4509-4518.
-
(2011)
Blood
, vol.118
, pp. 4509-4518
-
-
Li, Z.1
Cai, X.2
Cai, C.L.3
Wang, J.4
Zhang, W.5
-
22
-
-
84870766228
-
In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells
-
Soucie E, Hanssens K, Mercher T, Georgin-Lavialle S, Damaj G, et al. (2012) In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood 120: 4846-4849.
-
(2012)
Blood
, vol.120
, pp. 4846-4849
-
-
Soucie, E.1
Hanssens, K.2
Mercher, T.3
Georgin-Lavialle, S.4
Damaj, G.5
-
23
-
-
79951495806
-
Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit
-
Gerbaulet A, Wickenhauser C, Scholten J, Peschke K, Drube S, et al. (2011) Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood 117: 2012-2021.
-
(2011)
Blood
, vol.117
, pp. 2012-2021
-
-
Gerbaulet, A.1
Wickenhauser, C.2
Scholten, J.3
Peschke, K.4
Drube, S.5
-
25
-
-
41049104888
-
Mast cell-specific Cre/loxP-mediated recombination in vivo
-
Scholten J, Hartmann K, Gerbaulet A, Krieg T, Muller W, et al. (2008) Mast cell-specific Cre/loxP-mediated recombination in vivo. Transgenic Res 17: 307-315.
-
(2008)
Transgenic Res
, vol.17
, pp. 307-315
-
-
Scholten, J.1
Hartmann, K.2
Gerbaulet, A.3
Krieg, T.4
Muller, W.5
-
27
-
-
73949158887
-
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: Role of KIT D816V and effects of various targeted drugs
-
Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, et al. (2009) Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 114: 5342-5351.
-
(2009)
Blood
, vol.114
, pp. 5342-5351
-
-
Aichberger, K.J.1
Gleixner, K.V.2
Mirkina, I.3
Cerny-Reiterer, S.4
Peter, B.5
-
28
-
-
0037100321
-
Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene
-
DOI 10.1182/blood-2002-01-0203
-
Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C (2002) Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 100: 661-665. (Pubitemid 34761133)
-
(2002)
Blood
, vol.100
, Issue.2
, pp. 661-665
-
-
Yavuz, A.S.1
Lipsky, P.E.2
Yavuz, S.3
Metcalfe, D.D.4
Akin, C.5
-
29
-
-
23844451378
-
Identification of mast cell progenitors in adult mice
-
DOI 10.1073/pnas.0504197102
-
Chen CC, Grimbaldeston MA, Tsai M, Weissman IL, Galli SJ (2005) Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci U S A 102: 11408-11413. (Pubitemid 41153833)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.32
, pp. 11408-11413
-
-
Chen, C.-C.1
Grimbaldeston, M.A.2
Tsai, M.3
Weissman, I.L.4
Galli, S.J.5
-
30
-
-
29144472957
-
Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis
-
DOI 10.1073/pnas.0509148102
-
Arinobu Y, Iwasaki H, Gurish MF, Mizuno S, Shigematsu H, et al. (2005) Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci U S A 102: 18105-18110. (Pubitemid 41798509)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.50
, pp. 18105-18110
-
-
Arinobu, Y.1
Iwasaki, H.2
Gurish, M.F.3
Mizuno, S.-I.4
Shigematsu, H.5
Ozawa, H.6
Tenen, D.G.7
Austen, K.F.8
Akashi, K.9
-
31
-
-
0020606416
-
Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, P cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity
-
Ihle JN, Keller J, Oroszlan S, Henderson LE, Copeland TD, et al. (1983) Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J Immunol 131: 282-287. (Pubitemid 13067894)
-
(1983)
Journal of Immunology
, vol.131
, Issue.1
, pp. 282-287
-
-
Ihle, J.N.1
Keller, J.2
Oroszlan, S.3
-
32
-
-
0021350731
-
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan
-
Razin E, Ihle JN, Seldin D, Mencia-Huerta JM, Katz HR, et al. (1984) Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol 132: 1479-1486. (Pubitemid 14156069)
-
(1984)
Journal of Immunology
, vol.132
, Issue.3
, pp. 1479-1486
-
-
Razin, E.1
Ihle, J.N.2
Seldin, D.3
-
33
-
-
31544459272
-
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
-
DOI 10.1158/0008-5472.CAN-05-2050
-
Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, et al. (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66: 473-481. (Pubitemid 43166056)
-
(2006)
Cancer Research
, vol.66
, Issue.1
, pp. 473-481
-
-
Schittenhelm, M.M.1
Shiraga, S.2
Schroeder, A.3
Corbin, A.S.4
Griffith, D.5
Lee, F.Y.6
Bokemeyer, C.7
Deininger, M.W.N.8
Druker, B.J.9
Heinrich, M.C.10
-
34
-
-
78650019179
-
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
-
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
-
(2010)
Cancer Cell
, vol.18
, pp. 553-567
-
-
Figueroa, M.E.1
Abdel-Wahab, O.2
Lu, C.3
Ward, P.S.4
Patel, J.5
-
35
-
-
0023695019
-
Significance of systemic mast cell disease with associated hematologic disorders
-
Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG (1988) Significance of systemic mast cell disease with associated hematologic disorders. Cancer 62: 965-972.
-
(1988)
Cancer
, vol.62
, pp. 965-972
-
-
Travis, W.D.1
Li, C.Y.2
Yam, L.T.3
Bergstralh, E.J.4
Swee, R.G.5
-
36
-
-
70449706224
-
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
-
Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, et al. (2009) Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 114: 3769-3772.
-
(2009)
Blood
, vol.114
, pp. 3769-3772
-
-
Pardanani, A.1
Lim, K.H.2
Lasho, T.L.3
Finke, C.4
McClure, R.F.5
-
37
-
-
2642581620
-
Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: A histopathological challenge
-
DOI 10.1136/jcp.2003.014860
-
Horny HP, Sotlar K, Sperr WR, Valent P (2004) Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 57: 604-608. (Pubitemid 38725760)
-
(2004)
Journal of Clinical Pathology
, vol.57
, Issue.6
, pp. 604-608
-
-
Horny, H.-P.1
Sotlar, K.2
Sperr, W.R.3
Valent, P.4
-
38
-
-
48249135110
-
Acute lymphoblastic leukemia and cutaneous mastocytosis in two children
-
Masserot C, Adjaoud D, Haouy S, Deswarte C, Ballerini P, et al. (2008) Acute lymphoblastic leukemia and cutaneous mastocytosis in two children. Pediatr Blood Cancer 51: 444-445.
-
(2008)
Pediatr Blood Cancer
, vol.51
, pp. 444-445
-
-
Masserot, C.1
Adjaoud, D.2
Haouy, S.3
Deswarte, C.4
Ballerini, P.5
-
39
-
-
0029160095
-
Urticaria pigmentosa and acute lymphoblastic leukaemia
-
Lewis HM, Winter E, Darbyshire P, Yoong A, Marsden JR, et al. (1995) Urticaria pigmentosa and acute lymphoblastic leukaemia. J R Soc Med 88: 530P-531P.
-
(1995)
J R Soc Med
, vol.88
-
-
Lewis, H.M.1
Winter, E.2
Darbyshire, P.3
Yoong, A.4
Marsden, J.R.5
-
40
-
-
10144261890
-
Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase
-
Kitayama H, Tsujimura T, Matsumura I, Oritani K, Ikeda H, et al. (1996) Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 88: 995-1004. (Pubitemid 26333324)
-
(1996)
Blood
, vol.88
, Issue.3
, pp. 995-1004
-
-
Kitayama, H.1
Tsujimura, T.2
Matsumura, I.3
Oritani, K.4
Ikeda, H.5
Ishikawa, J.6
Okabe, M.7
Suzuki, M.8
Yamamura, K.-I.9
Matsuzawa, Y.10
Kitamura, Y.11
Kanakura, Y.12
-
41
-
-
33845751024
-
Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling
-
DOI 10.1128/MCB.01153-06
-
Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH (2007) Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol 27: 267-282. (Pubitemid 46013250)
-
(2007)
Molecular and Cellular Biology
, vol.27
, Issue.1
, pp. 267-282
-
-
Xiang, Z.1
Kreisel, F.2
Cain, J.3
Colson, A.4
Tomasson, M.H.5
-
42
-
-
78651316195
-
TET2 mutations in childhood leukemia
-
Langemeijer SM, Jansen JH, Hooijer J, van Hoogen P, Stevens-Linders E, et al. (2011) TET2 mutations in childhood leukemia. Leukemia 25: 189-192.
-
(2011)
Leukemia
, vol.25
, pp. 189-192
-
-
Langemeijer, S.M.1
Jansen, J.H.2
Hooijer, J.3
Van Hoogen, P.4
Stevens-Linders, E.5
-
43
-
-
84883742684
-
Epigenetics in clinical practice: The examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia
-
Estey EH (2013) Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia.
-
(2013)
Leukemia
-
-
Estey, E.H.1
-
44
-
-
84860827822
-
5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: Role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand
-
Ghanim V, Herrmann H, Heller G, Peter B, Hadzijusufovic E, et al. (2012) 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood 119: 4242-4252.
-
(2012)
Blood
, vol.119
, pp. 4242-4252
-
-
Ghanim, V.1
Herrmann, H.2
Heller, G.3
Peter, B.4
Hadzijusufovic, E.5
-
45
-
-
84863337757
-
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells
-
Tsai HC, Li H, Van Neste L, Cai Y, Robert C, et al. (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446.
-
(2012)
Cancer Cell
, vol.21
, pp. 430-446
-
-
Tsai, H.C.1
Li, H.2
Van Neste, L.3
Cai, Y.4
Robert, C.5
-
46
-
-
84876444289
-
Genomic impact of transient low-dose decitabine treatment on primary AML cells
-
Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, et al. (2013) Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 121: 1633-1643.
-
(2013)
Blood
, vol.121
, pp. 1633-1643
-
-
Klco, J.M.1
Spencer, D.H.2
Lamprecht, T.L.3
Sarkaria, S.M.4
Wylie, T.5
|